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Cytomegalovirus is known to induce long-lived humoral
and cellular immune responses that persist and increase
over time. In humans on average more than 5% of T
cells are CMV-reactive. We have previously reported
that mouse cytomegalovirus (MCMV) encoding the
unmodified TRP2 protein can induce immunity that
protects mice from challenge with the weakly immuno-
genic B16-F10 melanoma [Xu 2013]. This protective
immunity could be induced in mice with pre-existing
immunity to MCMV, overcoming a critical hurdle to
the clinical application of this strategy. Surprisingly, this
immunity to TRP2 was mediated by antibody. We have
extended these observations to the poorly immunogenic
B16BL6-D5 (D5) melanoma model, where we now
report that vaccination also provides protective immu-
nity. While anti-TRP2 immunity induced by MCMV is
humoral, it is as effective as vaccination with a GM-
CSF-secreting (GVAX) vaccine (D5-G6) that induces
tumor-specific T cell immunity. When we evaluated
MCMV-TRP2 in a therapeutic model, the vaccine was
ineffective as a single agent. We went on to investigate
whether the “inflating” immunity that MCMV is well
known for would lead to the co-development of a T cell
response long-term. Mice were vaccinated with MCMV-
TRP2 and followed long-term. Half of these mice were
challenged with viable D5 on day 14. Controls included
mice that were vaccinated with D5-G6 and followed
long-term. After more than 190 days from the initial
vaccination, mice were sacrificed and spleen and lymph
node cells were interrogated for an IFN-g response
following stimulation with D5, murine sarcoma cells, or
a peptide specific for MCMV. As expected, a large IFN-
g response was elicited by the MCMV peptide in
MCMV-vector immunized mice. In addition all vacci-
nated animals developed a detectable IFN-g response to
the D5 melanoma. The intensity of the T cell response
was similar in mice receiving MCMV-TRP2 and D5-G6.
Studies are ongoing to characterize the targets of this T
cell response and evaluate the mechanism(s) of MCMV-
TRP2-induced tumor elimination. While preliminary,
the well-established ability of CMV to induce and main-
tain high-frequency antigen-specific responses, com-
bined with our results, suggest that this strategy may
provide an opportunity to augment the anti-cancer
immune responses.
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